Table 1 Characteristics of the patients
From: A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
All evaluable patients, n = 23 | Median (range) or No. (%) |
|---|---|
Age, year | 59 (49–72) |
Gender | Â |
Male | 11 (48) |
Female | 12 (52) |
ECOG performance status | Â |
0–2 | 19 (83) |
3–4 | 4 (17) |
Monoclonal type | Â |
IgA | 6 (26) |
IgG | 7 (30) |
k light chain | 3 (13) |
λ light chain | 4 (18) |
others(IgD, IgM) | 3 (13) |
Extramedullary plasmacytomas | 9 (39) |
Complex karyotype | 5 (22) |
Cytogenetic profiles* | 17 (74) |
R-ISS stage | Â |
I | 6 (26) |
II | 6 (26) |
III | 11 (48) |
Time since diagnosis, year | 2.9 (0.4–13.4) |
MM burden at enrollment | Â |
Serum M protein (g/L) | 15.9 (0.5–58.9) |
Myeloma cells in bone marrow by FCM (%) | 11.9 (0.2–56.1) |
Refractory/Relapse at enrollment | Â |
Refractory to the last treatment | 14 (61) |
Relapse after the last treatment | 9 (39) |
Previous therapies | 4 (2–9) |
Prior ASCT | 3 (13) |
Prior proteasome inhibitors | Â |
Bortezomib | 23 (100) |
Ixazomib | 4 (17) |
Prior immunomodulatory drugs | Â |
Lenalidomide | 13 (57) |
Thalidomide | 15 (65) |
Pomalidomide | 1 (4) |